Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Rheumatology Reviews
  4. Volume 21, Issue 2
  5. Article
Volume 21, Issue 2
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Methotrexate (MTX) is the primarily used disease-modifying antirheumatic drug (DMARD) for the treatment of Rheumatoid Arthritis (RA). MTX is a safe agent, even when used for years - provided that treatment is regularly monitored and prescribers follow some simple rules, such as prescribing tablets of a single strength only. Proper patient education contributes greatly to safe treatment. The knowledge of important pharmacologic facts, possible interactions, and clinical warning signs also helps to prevent or recognize intoxications early.

Therefore, this review addresses key aspects regarding the safety of MTX. In this respect, it includes adverse events, possible interactions with frequently used drugs and details on the rare but life-threatening intoxication, , due to erroneous daily intake.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971317122240626053727
2024-07-08
2025-05-21

  • From This Site

    /content/journals/crr/10.2174/0115733971317122240626053727
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WeinblattM.E. Methotrexate: who would have predicted its importance in Rheumatoid arthritis?Arthritis Res. Ther.201820110310.1186/s13075‑018‑1599‑729848356
     [Google Scholar]
  2. BraunJ. Methotrexate: optimizing the efficacy in Rheumatoid arthritis.Ther. Adv. Musculoskelet. Dis.20113315115810.1177/1759720X1140863522870474
     [Google Scholar]
  3. EdmundsonW.F. GuyW.B. Treatment of psoriasis with folic acid antagonists.Arch. Dermatol.195878220020310.1001/archderm.1958.0156008006001013558707
     [Google Scholar]
  4. GubnerR. AugustS. GinsbergV. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in Rheumatoid arthritis and psoriasis.Am. J. Med. Sci.1951221217618210.1097/00000441‑195102000‑0000914799481
     [Google Scholar]
  5. PincusT. GibsonK.A. CastrejónI. Update on methotrexate as the anchor drug for Rheumatoid arthritis.Bull. Hosp. Jt. Dis.20137171Suppl. 1S9S1924219036
     [Google Scholar]
  6. KrieckaertC.L. NurmohamedM.T. WolbinkG.J. Methotrexate reduces immunogenicity in adalimumab treated Rheumatoid arthritis patients in a dose dependent manner.Ann. Rheum. Dis.201271111914191510.1136/annrheumdis‑2012‑20154422586169
     [Google Scholar]
  7. BurmesterG.R. KivitzA.J. KupperH. ArulmaniU. FlorentinusS. GossS.L. RathmannS.S. FleischmannR.M. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.Ann. Rheum. Dis.20157461037104410.1136/annrheumdis‑2013‑20476924550168
     [Google Scholar]
  8. WHOWorld Health Organization Model List of Essential Medicines : 22nd List.2021Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02
  9. Hexal. Fachinformation MTX HEXAL® Tabletten.2022Available from: https://www.hexal.biz/praeparate/dokumente/fi/51014344_TAB_HX_FI_it.pdf
  10. FDAFDA. METHOTREXATE tablets, for oral use.2020Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/040054s015,s016,s017.pdf
  11. NHS. Methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care).2022Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwi35KC6_Y6EAxWjnf0HHSFEC0oQFnoECBUQAQ&url=https%3A%2F%2Fwww.england.nhs.uk%2Fwp-content%2Fuploads%2F2022%2F07%2FB1621_xvii_methotrexate-oral-and-subcutaneous-for-patients-in-adult-services-excluding-cancer-care.docx&usg=AOvVaw2ktZ4xpmxoTwfe-YMA9A6j&opi=89978449
  12. FiehnC. HolleJ. Iking-KonertC. LeipeJ. WeselohC. FrerixM. AltenR. BehrensF. BaerwaldC. BraunJ. BurkhardtH. BurmesterG. DetertJ. GaubitzM. GauseA. Gromnica-IhleE. KellnerH. KrauseA. KuipersJ. LorenzH.M. Müller-LadnerU. NothackerM. NüssleinH. Rubbert-RothA. SchneiderM. Schulze-KoopsH. SeitzS. SitterH. SpeckerC. TonyH.P. WassenbergS. WollenhauptJ. KrügerK. S2e guideline: Treatment of Rheumatoid arthritis with disease-modifying drugs.Z. Rheumatol.201877Suppl. 2355310.1007/s00393‑018‑0481‑y29968101
     [Google Scholar]
  13. SmolenJ.S. LandewéR.B.M. BergstraS.A. KerschbaumerA. SeprianoA. AletahaD. CaporaliR. EdwardsC.J. HyrichK.L. PopeJ.E. de SouzaS. StammT.A. TakeuchiT. VerschuerenP. WinthropK.L. BalsaA. BathonJ.M. BuchM.H. BurmesterG.R. ButtgereitF. CardielM.H. ChatzidionysiouK. CodreanuC. CutoloM. den BroederA.A. El AoufyK. FinckhA. FonsecaJ.E. GottenbergJ.E. HaavardsholmE.A. IagnoccoA. LauperK. LiZ. McInnesI.B. MyslerE.F. NashP. PoorG. RisticG.G. RivelleseF. Rubbert-RothA. Schulze-KoopsH. StoilovN. StrangfeldA. van der Helm-van MilA. van DuurenE. Vliet VlielandT.P.M. WesthovensR. van der HeijdeD. EULAR recommendations for the management of Rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.Ann. Rheum. Dis.202382131810.1136/ard‑2022‑22335636357155
     [Google Scholar]
  14. GossecL. BaraliakosX. KerschbaumerA. de WitM. McInnesI. DougadosM. PrimdahlJ. McGonagleD.G. AletahaD. BalanescuA. BalintP.V. BertheussenH. BoehnckeW.H. BurmesterG.R. CaneteJ.D. DamjanovN.S. KragstrupT.W. KvienT.K. LandewéR.B.M. LoriesR.J.U. Marzo-OrtegaH. PoddubnyyD. Rodrigues ManicaS.A. SchettG. VealeD.J. Van den BoschF.E. van der HeijdeD. SmolenJ.S. EULAR recommendations for the management of Psoriatic arthritis with pharmacological therapies: 2019 update.Ann. Rheum. Dis.2020796700.171210.1136/annrheumdis‑2020‑21715932434812
     [Google Scholar]
  15. CoatesL.C. MerolaJ.F. GriebS.M. MeaseP.J. Callis DuffinK. Methotrexate in psoriasis and Psoriatic arthritis.J. Rheumatol.202096313510.3899/jrheum.20012432482765
     [Google Scholar]
  16. ButtgereitF. BrabantT. DingesH. HiemerI. KaplaniM. KiltzU. KyburzD. ReißhauerA. SchneiderM. WeselohC. DejacoC. DGRh DGG DGOOC Rheuma-Liga DGIM SGR DGPMR ÖGR S3 guidelines on treatment of polymyalgia rheumatica.Z. Rheumatol.201877542944110.1007/s00393‑018‑0476‑829845555
     [Google Scholar]
  17. FanouriakisA. KostopoulouM. AlunnoA. AringerM. BajemaI. BoletisJ.N. CerveraR. DoriaA. GordonC. GovoniM. HoussiauF. JayneD. KouloumasM. KuhnA. LarsenJ.L. LerstrømK. MoroniG. MoscaM. SchneiderM. SmolenJ.S. SvenungssonE. TesarV. TincaniA. TroldborgA. van VollenhovenR. WenzelJ. BertsiasG. BoumpasD.T. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.Ann. Rheum. Dis.201978673674510.1136/annrheumdis‑2019‑21508930926722
     [Google Scholar]
  18. KrasseltM.L. HolleJ.U. ANCA-assoziierte Vaskulitis.Inn. Med. (Heidelb.)202263994796010.1007/s00108‑022‑01386‑w35925127
     [Google Scholar]
  19. WentzellN. KollhorstB. ReinoldJ. HaugU. Use of methotrexate in girls and women of childbearing age, occurrence of methotrexate-exposed pregnancies and their outcomes in Germany: A claims data analysis.Clin. Drug Investig.202343210911710.1007/s40261‑022‑01227‑636542272
     [Google Scholar]
  20. CronsteinB.N. AuneT.M. Methotrexate and its mechanisms of action in inflammatory arthritis.Nat. Rev. Rheumatol.202016314515410.1038/s41584‑020‑0373‑932066940
     [Google Scholar]
  21. GreenP.G. BasbaumA.I. HelmsC. LevineJ.D. Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat.Proc. Natl. Acad. Sci.199188104162416510.1073/pnas.88.10.41622034661
     [Google Scholar]
  22. NesherG. MatesM. ZevinS. Effect of caffeine consumption on efficacy of methotrexate in Rheumatoid arthritis.Arthritis Rheum.200348257157210.1002/art.1076612571869
     [Google Scholar]
  23. Benito-GarciaE. HellerJ.E. ChibnikL.B. MaherN.E. MatthewsH.M. BilicsJ.A. WeinblattM.E. ShadickN.A. Dietary caffeine intake does not affect methotrexate efficacy in patients with Rheumatoid arthritis.J. Rheumatol.20063371275128116821266
     [Google Scholar]
  24. SwansonD.L. BarnesS.A. Mengden KoonS.J. El-AzharyR.A. Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis.Int. J. Dermatol.200746215715910.1111/j.1365‑4632.2006.02954.x17269967
     [Google Scholar]
  25. CronsteinB.N. SitkovskyM. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.Nat. Rev. Rheumatol.2017131415110.1038/nrrheum.2016.17827829671
     [Google Scholar]
  26. PeresR.S. LiewF.Y. TalbotJ. CarregaroV. OliveiraR.D. AlmeidaS.L. FrançaR.F.O. DonateP.B. PintoL.G. FerreiraF.I.S. CostaD.L. DemarqueD.P. GouveaD.R. LopesN.P. QueirozR.H.C. SilvaJ.S. FigueiredoF. Alves-FilhoJ.C. CunhaT.M. FerreiraS.H. Louzada-JuniorP. CunhaF.Q. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in Rheumatoid arthritis.Proc. Natl. Acad. Sci.201511282509251410.1073/pnas.142479211225675517
     [Google Scholar]
  27. BitounS. NocturneG. LyB. KrzysiekR. RoquesP. PruvostA. PaolettiA. PascaudJ. DönnesP. FlorenceK. GleizesA. Hincelin-MeryA. AllezM. Hacein-Bey-AbinaS. MackayF. PallardyM. Le GrandR. MarietteX. Methotrexate and BAFF interaction prevents immunization against TNF inhibitors.Ann. Rheum. Dis.201877101463147010.1136/annrheumdis‑2018‑21340329936438
     [Google Scholar]
  28. HuffmanD.H. WanS.H. AzarnoffD.L. HoogstratenB. Pharmacokinetics of methotrexate.Clin. Pharmacol. Ther.1973144part157257910.1002/cpt1973144part15724723265
     [Google Scholar]
  29. DalrympleJ.M. StampL.K. O’DonnellJ.L. ChapmanP.T. ZhangM. BarclayM.L. Pharmacokinetics of oral methotrexate in patients with Rheumatoid arthritis.Arthritis Rheum.200858113299330810.1002/art.2403418975321
     [Google Scholar]
  30. SherbiniA.A. GwinnuttJ.M. HyrichK.L. AdebajoA. AhmedK. Al-AnsariA. AmarasenaR. BukhariM. CallanM. Chelliahe.g. ChinoyH. CooperA. DasguptaB. DavisM. GallowayJ. GoughA. GreenM. GullickN. HamiltonJ. HassanW. HiderS. HyrichK. KamathS. KnightS. LaneS. LeeM. LevyS. MacphieL. MarguerieC. MarshallT. MathewsC. McKennaF. NazS. PerryM. PollardL. QuiltyB. RobertsonL. RoyD. SandersP. SaravananV. ScottD. SmithG. SmithR. SymmonsD. TehL-S. VinerN. VerstappenS.M.M. Rates and predictors of methotrexate-related adverse events in patients with early Rheumatoid arthritis: Results from a nationwide UK study.Rheumatology202261103930393810.1093/rheumatology/keab91735078225
     [Google Scholar]
  31. TanakaY. Subcutaneous injection of methotrexate: Advantages in the treatment of Rheumatoid arthritis.Mod. Rheumatol.202233463363936525530
     [Google Scholar]
  32. BraunJ. KästnerP. FlaxenbergP. WährischJ. HankeP. DemaryW. von HinüberU. RockwitzK. HeitzW. PichlmeierU. Guimbal-SchmolckC. BrandtA. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active Rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.Arthritis Rheum.2008581738110.1002/art.2314418163521
     [Google Scholar]
  33. SchiffM.H. JaffeJ.S. FreundlichB. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with Rheumatoid arthritis: Drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.Ann. Rheum. Dis.20147381549155110.1136/annrheumdis‑2014‑20522824728329
     [Google Scholar]
  34. StampL.K. BarclayM.L. O’DonnellJ.L. ZhangM. DrakeJ. FramptonC. ChapmanP.T. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with Rheumatoid arthritis.J. Rheumatol.201138122540254710.3899/jrheum.11048121965639
     [Google Scholar]
  35. Gaujoux-VialaC. HudryC. ZinovievaE. Herman-DemarsH. FlipoR.M. MTX optimization or adding bDMARD equally improve disease activity in Rheumatoid arthritis: Results from the prospective study STRATEGE.Rheumatology202161127028010.1093/rheumatology/keab27433774669
     [Google Scholar]
  36. WasilaM. BeiseU. Inflammatory-rheumatic joint diseases.mediX2019Available from: https://www.medix.ch/wissen/guidelines/entzuendlich-rheumatische-gelenkerkrankungen/
    [Google Scholar]
  37. SheaB. SwindenM.V. Tanjong GhogomuE. OrtizZ. KatchamartW. RaderT. BombardierC. WellsG.A. TugwellP. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for Rheumatoid arthritis.Cochrane Libr.201320147CD00095110.1002/14651858.CD000951.pub223728635
     [Google Scholar]
  38. MazaudC. FardetL. Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: A systematic review and meta-analysis of randomized placebo-controlled trials.Br. J. Dermatol.2017177497898610.1111/bjd.1537728182264
     [Google Scholar]
  39. Van EdeA.E. LaanR.F.J.M. RoodM.J. HuizingaT.W.J. Van De LaarM.A.F.J. DenderenC.J.V. WestgeestT.A.A. RommeT.C. De RooijD.J.R.A.M. JacobsM.J.M. De BooT.M. Van Der WiltG.J. SeverensJ.L. HartmanM. KrabbeP.F.M. DijkmansB.A.C. BreedveldF.C. Van De PutteL.B.A. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in Rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study.Arthritis Rheum.20014471515152410.1002/1529‑0131(200107)44:7<1515::AID‑ART273>3.0.CO;2‑711465701
     [Google Scholar]
  40. KhannaD. ParkG.S. PaulusH.E. SimpsonK.M. ElashoffD. CohenS.B. EmeryP. DorrierC. FurstD.E. Reduction of the efficacy of methotrexate by the use of folic acid: Post hoc analysis from two randomized controlled studies.Arthritis Rheum.200552103030303810.1002/art.2129516200612
     [Google Scholar]
  41. SulliA. Response to methotrexate treatment in Rheumatoid arthritis patients receiving folic acid supplementation.Arthritis Rheumatol.202274suppl 9
     [Google Scholar]
  42. ConwayR. LowC. CoughlanR.J. O’DonnellM.J. CareyJ.J. Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials.Semin. Arthritis Rheum.201545215616210.1016/j.semarthrit.2015.05.00326088004
     [Google Scholar]
  43. VisserK. KatchamartW. LozaE. Martinez-LopezJ.A. SalliotC. TrudeauJ. BombardierC. CarmonaL. van der HeijdeD. BijlsmaJ.W.J. BoumpasD.T. CanhaoH. EdwardsC.J. HamuryudanV. KvienT.K. LeebB.F. Martín-MolaE.M. MielantsH. Müller-LadnerU. MurphyG. ØstergaardM. PereiraI.A. Ramos-RemusC. ValentiniG. ZochlingJ. DougadosM. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on Rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.Ann. Rheum. Dis.20096871086109310.1136/ard.2008.09447419033291
     [Google Scholar]
  44. SchmajukG. MiaoY. YazdanyJ. BoscardinW.J. DaikhD.I. SteinmanM.A. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.Arthritis Care Res.20146681159116610.1002/acr.2229424470205
     [Google Scholar]
  45. AtallahE. GroveJ.I. CrooksC. Burden-TehE. AbhishekA. MoreeaS. JordanK.M. AlaA. HutchinsonD. AspinallR.J. MurphyR. AithalG.P. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.J. Hepatol.202378598999710.1016/j.jhep.2022.12.03436702175
     [Google Scholar]
  46. DawwasM.F. AithalG.P. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.Aliment. Pharmacol. Ther.201440893894810.1111/apt.1291225185870
     [Google Scholar]
  47. ConwayR. LowC. CoughlanR.J. O’DonnellM.J. CareyJ.J. Methotrexate and lung disease in Rheumatoid arthritis: A meta-analysis of randomized controlled trials.Arthritis Rheumatol.201466480381210.1002/art.3832224757133
     [Google Scholar]
  48. SparksJ.A. DellaripaP.F. GlynnR.J. PaynterN.P. XuC. RidkerP.M. SolomonD.H. Pulmonary adverse events in patients receiving low-dose methotrexate in the randomized, double-blind, placebo-controlled cardiovascular inflammation reduction trial.Arthritis Rheumatol.202072122065207110.1002/art.4145232741143
     [Google Scholar]
  49. FragoulisG.E. ConwayR. NikiphorouE. Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature.Rheumatology201958111900190610.1093/rheumatology/kez33731504978
     [Google Scholar]
  50. FragoulisG.E. NikiphorouE. LarsenJ. KorstenP. ConwayR. Methotrexate-associated pneumonitis and Rheumatoid arthritis-interstitial lung disease: Current concepts for the diagnosis and treatment.Front. Med.2019623810.3389/fmed.2019.0023831709258
     [Google Scholar]
  51. MehtaP. RedheadG. NairA. SparksJ.A. PorterJ.C. Can we finally exonerate methotrexate as a factor in causing or exacerbating fibrotic interstitial lung disease in patients with Rheumatoid arthritis?Clin. Rheumatol.202241102925292810.1007/s10067‑022‑06245‑535729371
     [Google Scholar]
  52. JugeP.A. LeeJ.S. LauJ. Kawano-DouradoL. Rojas SerranoJ. SebastianiM. KoduriG. MattesonE. BonfiglioliK. SawamuraM. KairallaR. CavagnaL. Bozzalla CassioneE. ManfrediA. MejiaM. Rodríguez-HenriquezP. González-PérezM.I. Falfán-ValenciaR. Buendia-RoldánI. Pérez-RubioG. EbsteinE. GazalS. BorieR. OttavianiS. KannengiesserC. WallaertB. UzunhanY. NunesH. ValeyreD. Saidenberg-Kermanac’hN. BoissierM.C. Wemeau-StervinouL. FlipoR.M. Marchand-AdamS. RichetteP. AllanoreY. DromerC. TruchetetM.E. RichezC. SchaeverbekeT. LiotéH. ThabutG. DeaneK.D. SolomonJ.J. DoyleT. RyuJ.H. RosasI. HolersV.M. BoileauC. DebrayM.P. PorcherR. SchwartzD.A. VassalloR. CrestaniB. DieudéP. Methotrexate and Rheumatoid arthritis associated interstitial lung disease.Eur. Respir. J.2021572200033710.1183/13993003.00337‑202032646919
     [Google Scholar]
  53. IbfeltE.H. JacobsenR.K. KoppT.I. CordtzR.L. JakobsenA.S. SeersholmN. ShakerS.B. DreyerL. Methotrexate and risk of interstitial lung disease and respiratory failure in Rheumatoid arthritis: A nationwide population-based study.Rheumatology202160134635210.1093/rheumatology/keaa32732780828
     [Google Scholar]
  54. DawsonJ.K. QuahE. EarnshawB. AmoasiiC. MudawiT. SpencerL.G. Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.Rheumatol. Int.20214161055106410.1007/s00296‑020‑04773‑433515067
     [Google Scholar]
  55. SolomonD.H. GlynnR.J. KarlsonE.W. LuF. CorriganC. CollsJ. XuC. MacFadyenJ. BarbhaiyaM. BerlinerN. DellaripaP.F. EverettB.M. PradhanA.D. HammondS.P. MurrayM. RaoD.A. RitterS.Y. RutherfordA. SparksJ.A. StrattonJ. SuhD.H. TedeschiS.K. VanniK.M.M. PaynterN.P. RidkerP.M. Adverse effects of low-dose methotrexate.Ann. Intern. Med.2020172636938010.7326/M19‑336932066146
     [Google Scholar]
  56. RidkerP.M. EverettB.M. PradhanA. MacFadyenJ.G. SolomonD.H. ZaharrisE. MamV. HasanA. RosenbergY. IturriagaE. GuptaM. TsigoulisM. VermaS. ClearfieldM. LibbyP. GoldhaberS.Z. SeagleR. OforiC. SaklayenM. ButmanS. SinghN. Le MayM. BertrandO. JohnstonJ. PaynterN.P. GlynnR.J. Low-dose methotrexate for the prevention of atherosclerotic events.N. Engl. J. Med.2019380875276210.1056/NEJMoa180979830415610
     [Google Scholar]
  57. SparksJ.A. BarbhaiyaM. KarlsonE.W. RitterS.Y. RaychaudhuriS. CorriganC.C. LuF. SelhubJ. ChasmanD.I. PaynterN.P. RidkerP.M. SolomonD.H. Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the cardiovascular inflammation reduction trial-adverse events (CIRT-AE) Study.Semin. Arthritis Rheum.201747113314210.1016/j.semarthrit.2017.02.00328284844
     [Google Scholar]
  58. VanniK.M.M. BerlinerN. PaynterN.P. GlynnR.J. MacFadyenJ. CollsJ. LuF. XuC. RidkerP.M. SolomonD.H. Adverse effects of low-dose methotrexate in a randomized double-blind placebo-controlled trial: Adjudicated hematologic and skin cancer outcomes in the cardiovascular inflammation reduction trial.ACR Open Rheumatol.202021269770410.1002/acr2.1118733201596
     [Google Scholar]
  59. PolesieS. GillstedtM. SchmidtS.A.J. EgebergA. PottegårdA. KristensenK. Use of methotrexate and risk of skin cancer: A nationwide case–control study.Br. J. Cancer202312871311131910.1038/s41416‑023‑02172‑736739322
     [Google Scholar]
  60. YanM.K. WangC. WolfeR. MarV.J. WlukaA.E. Association between low-dose methotrexate exposure and melanoma.JAMA Dermatol.2022158101157116610.1001/jamadermatol.2022.333736044236
     [Google Scholar]
  61. OgdieA. Maksabedian HernandezE.J. ShawY. StolshekB. MichaudK. Side effects of methotrexate and tumor necrosis factor inhibitors: Differences in tolerability among patients with psoriatic arthritis and Rheumatoid arthritis.ACR Open Rheumatol.202241193594110.1002/acr2.1146735971643
     [Google Scholar]
  62. JafariF. ArastehO. HosseinjaniH. AllahyariA. Ataei AzimiS. AskariV.R. A critical review of methotrexate clinical interactions: Role of transporters.Expert Opin. Drug Metab. Toxicol.20231929110710.1080/17425255.2023.219332536946211
     [Google Scholar]
  63. Preet SinghY. AggarwalA. MisraR. AgarwalV. Low-dose methotrexate-induced pancytopenia.Clin. Rheumatol.2007261848710.1007/s10067‑006‑0301‑716636937
     [Google Scholar]
  64. CudmoreJ. SeftelM. SislerJ. ZarychanskiR. Methotrexate and trimethoprim-sulfamethoxazole: Toxicity from this combination continues to occur.Can. Fam. Physician2014601535624452563
     [Google Scholar]
  65. SathiN. AckahJ. DawsonJ. Methotrexate induced neutropenia associated with coprescription of penicillins: Serious and under-reported?Rheumatology200645336136210.1093/rheumatology/kei20016332953
     [Google Scholar]
  66. Al-QuteimatO.M. Al-BadainehM.A. Methotrexate and trimethoprim-sulphamethoxazole: Extremely serious and life-threatening combination.J. Clin. Pharm. Ther.201338320320510.1111/jcpt.1206023521709
     [Google Scholar]
  67. KwonO.C. LeeJ.S. KimY.G. LeeC.K. YooB. HongS. Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole.Clin. Rheumatol.201837123215322010.1007/s10067‑018‑4005‑629383453
     [Google Scholar]
  68. WattsC.S. SciasciJ.N. PauleyJ.L. PanettaJ.C. PeiD. ChengC. ChristensenC.M. MikkelsenT.S. PuiC.H. JehaS. RellingM.V. Prophylactic trimethoprim- sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate.J. Pediatr. Hematol. Oncol.201638644945210.1097/MPH.000000000000060627322715
     [Google Scholar]
  69. ArslanA. ZainM.A. MukhtarM. UllahW. RoomiS. Methotrexate and doxycycline interaction: A rare cause of pancytopenia.BMJ Case Rep.2019125e22929610.1136/bcr‑2019‑22929631154348
     [Google Scholar]
  70. Tortajada-IturenJ.J. Ordovás-BainesJ.P. Llopis-SalviaP. Jiménez- TorresN.V. High-dose methotrexate-doxycycline interaction.Ann. Pharmacother.1999337-880480810.1345/aph.1823610466909
     [Google Scholar]
  71. IbrahemE.M. El-gendiS.S. MahmoudA.A. Abdel-AalS.M. MohammedH.S.E-D. Efficacy of doxycycline as a combination therapy in the treatment of Rheumatoid arthritis: A randomized controlled clinical trial.Egypt. J. Intern. Med.2021331310.1186/s43162‑021‑00032‑5
     [Google Scholar]
  72. O’DellJ.R. ElliottJ.R. MallekJ.A. MikulsT.R. WeaverC.A. GlicksteinS. BlakelyK.M. HauschR. LeffR.D. Treatment of early seropositive Rheumatoid arthritis: Doxycycline plus methotrexate versus methotrexate alone.Arthritis Rheum.200654262162710.1002/art.2162016447240
     [Google Scholar]
  73. VanhoofJ. LandeweS. Van WijngaerdenE. GeusensP. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with Rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors.Ann. Rheum. Dis.200362121241124210.1136/ard.2002.00459814644871
     [Google Scholar]
  74. FragoulisG.E. NikiphorouE. DeyM. ZhaoS.S. CourvoisierD.S. ArnaudL. AtzeniF. BehrensG.M.N. BijlsmaJ.W.J. BöhmP. ConstantinouC.A. Garcia-DiazS. KapetanovicM.C. LauperK. LuísM. MorelJ. NagyG. PolverinoE. van RompayJ. SebastianiM. StrangfeldA. de ThurahA. GallowayJ. HyrichK.L. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.Ann. Rheum. Dis.202382674275310.1136/ard‑2022‑22333536328476
     [Google Scholar]
  75. HolroydC.R. SethR. BukhariM. MalaviyaA. HolmesC. CurtisE. ChanC. YusufM.A. LitwicA. SmolenS. TopliffeJ. BennettS. HumphreysJ. GreenM. LedinghamJ. The british society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis.Rheumatology2019582e3e4210.1093/rheumatology/key20830137552
     [Google Scholar]
  76. KneitzC. KrügerK. Infection prophylaxis in rheumatic diseases.Z. Rheumatol.202180214915710.1007/s00393‑020‑00938‑533326041
     [Google Scholar]
  77. FiehnC. LeipeJ. WeselohC. BergnerR. KrügerK. Assessment of interactions and dosage recommendations of synthetic DMARDs—Evidence-based and consensus-based recommendations based on a systematic literature search.Z. Rheumatol.202382215116210.1007/s00393‑022‑01308‑z36633662
     [Google Scholar]
  78. ParkJ.K. LeeY.J. KangE.H. ShinK. KimM.J. HaY.J. ChoiS.R. ParkJ.W. KimM.H. KimJ.Y. JungJ.I. ChoiY. WinthropK.L. LeeE.B. Effect of the methotrexate discontinuation for 1 versus 2 weeks on vaccine response to seasonal influenza vaccine in Rheumatoid arthritis: A noninferiority randomized controlled trial.Arthritis Rheumatol.202310.1002/art.4231837410775
     [Google Scholar]
  79. ParkJ.K. LeeY.J. ShinK. HaY.J. LeeE.Y. SongY.W. ChoiY. WinthropK.L. LeeE.B. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with Rheumatoid arthritis: A randomised clinical trial.Ann. Rheum. Dis.2018776annrheumdis-2018-21322210.1136/annrheumdis‑2018‑21322229572291
     [Google Scholar]
  80. WangX. SongY. WangJ. HeJ. LiuR. LiX. HuangH. ZhangJ. Effect of proton pump inhibitors on high-dose methotrexate elimination: A systematic review and meta-analysis.Int. J. Clin. Pharm.2020421233010.1007/s11096‑019‑00958‑531916121
     [Google Scholar]
  81. SantucciR. LevêqueD. KemmelV. LutzP. GéroutA.C. N’guyenA. LescouteA. SchneiderF. BergeratJ.P. HerbrechtR. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.Anticancer Res.201030396396520393020
     [Google Scholar]
  82. BezabehS. MackeyA.C. KluetzP. JapparD. KorvickJ. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.Oncologist201217455055410.1634/theoncologist.2011‑043122477728
     [Google Scholar]
  83. TaoD. WangH. XiaF. MaW. Pancytopenia due to possible drug–drug interactions between low-dose methotrexate and proton pump inhibitors.Drug Healthc. Patient Saf.202214757810.2147/DHPS.S35019435607639
     [Google Scholar]
  84. KumarC. KuhnM. HerrmannK. LeuchtenN. AringerM. Severe methotrexate toxicity in elderly patients under diuretics.RMD Open2024101e00382710.1136/rmdopen‑2023‑00382738176739
     [Google Scholar]
  85. VialT. PatatA.M. BoelsD. CastellanD. VillaA. TheophileH. TorrentsR. KassaiB. Adverse consequences of low- dose methotrexate medication errors: Data from French poison control and pharmacovigilance centers.Joint Bone Spine201986335135510.1016/j.jbspin.2018.09.00630243781
     [Google Scholar]
  86. HallJ.J. BolinaM. ChatterleyT. JamaliF. Interaction between low-dose methotrexate and nonsteroidal anti-inflammatory drugs, penicillins, and proton pump inhibitors.Ann. Pharmacother.201751216317810.1177/106002801667203527701081
     [Google Scholar]
  87. Bourré-TessierJ. HaraouiB. Methotrexate drug interactions in the treatment of Rheumatoid arthritis: A systematic review.J. Rheumatol.20103771416142110.3899/jrheum.09015320436072
     [Google Scholar]
  88. SvanströmH. LundM. MelbyeM. PasternakB. Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with Rheumatoid arthritis.Pharmacoepidemiol. Drug Saf.201827888589310.1002/pds.455529797447
     [Google Scholar]
  89. Al-KhaliliO. MikulsT.R. O’DellJ.R. EnglandB.R. Methotrexate and NSAIDs in Rheumatoid arthritis— Confirmation of a known NSAIDs adverse effect rather than a dangerous combination.Pharmacoepidemiol. Drug Saf.20182712142910.1002/pds.467030421828
     [Google Scholar]
  90. ZhangX. DonnanP.T. BellS. GuthrieB. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: Systematic review and meta-analysis.BMC Nephrol.201718125610.1186/s12882‑017‑0673‑828764659
     [Google Scholar]
  91. PreissnerS. SiramshettyV.B. DunkelM. SteinbornP. LuftF.C. PreissnerR. Pain-prescription differences: An analysis of 500,000 discharge summaries.Curr. Drug Res. Rev.2019111586610.2174/187447371166618091109184630207223
     [Google Scholar]
  92. RattayB. BenndorfR.A. Drug-induced idiosyncratic agranulocytosis: Infrequent but dangerous.Front. Pharmacol.20211272771710.3389/fphar.2021.72771734483939
     [Google Scholar]
  93. HuberM. AndersohnF. SarganasG. BronderE. KlimpelA. ThomaeM. KonzenC. KreutzR. GarbeE. Metamizole-induced agranulocytosis revisited: Results from the prospective berlin case–control surveillance study.Eur. J. Clin. Pharmacol.201571221922710.1007/s00228‑014‑1777‑825378038
     [Google Scholar]
  94. HedenmalmK. SpigsetO. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole).Eur. J. Clin. Pharmacol.200258426527410.1007/s00228‑002‑0465‑212136373
     [Google Scholar]
  95. StammschulteT. LudwigW.D. MühlbauerB. BronderE. Gundert-RemyU. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990–2012.Eur. J. Clin. Pharmacol.20157191129113810.1007/s00228‑015‑1895‑y26169297
     [Google Scholar]
  96. HoffmannF. BantelC. JobskiK. Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985-2017.Basic Clin. Pharmacol. Toxicol.2020126211612510.1111/bcpt.1331031449718
     [Google Scholar]
  97. BressolleF. BolognaC. KinowskiJ.M. SanyJ. CombeB. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in Rheumatoid arthritis patients.Ann. Rheum. Dis.199857211011310.1136/ard.57.2.1109613341
     [Google Scholar]
  98. YaziciY. ErkanD. HarrisonM.J. NikolovN.P. PagetS.A. Methotrexate use in Rheumatoid arthritis is associated with few clinically significant liver function test abnormalities.Clin. Exp. Rheumatol.200523451752016095122
     [Google Scholar]
  99. YaziciY. SokkaT. KautiainenH. SwearingenC. KulmanI. PincusT. Long term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely the result of laboratory abnormalities.Ann. Rheum. Dis.200564220721110.1136/ard.2004.02340815208176
     [Google Scholar]
  100. HirschS. Methotrexat: Todesfälle durch falsche Dosis.Dtsch. Arztebl. Int.20201173A-76
     [Google Scholar]
  101. SchicchiA. ScaravaggiG. PetroliniV.M. MaloviniA. LonatiD. CrevaniM. BuscagliaE. LocatelliC.A. Poisoning related to therapeutic error in prolonged low-dose methotrexate treatment.Br. J. Clin. Pharmacol.20218752385239110.1111/bcp.1465233179288
     [Google Scholar]
  102. BhargavaM. KoppC.R. NaiduS. DhibarD.P. SarochA. KhadwalA. NarangT. JainS. KhullarA. LeishangthemB. SharmaA. KumarS. SharmaS. JainS. DhirV. Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity a randomized controlled trial.Arthritis Res. Ther.20232518210.1186/s13075‑023‑03054‑237208770
     [Google Scholar]
  103. AjmaniS. Preet SinghY. PrasadS. ChowdhuryA. AggarwalA. LawrenceA. MisraR. MishraR. AgarwalV. Methotrexate-induced pancytopenia: A case series of 46 patients.Int. J. Rheum. Dis.201720784685110.1111/1756‑185X.1300428261918
     [Google Scholar]
  104. SinicinaI. MayrB. MallG. KeilW. Deaths following methotrexate overdoses by medical staff.J. Rheumatol.200532102009201116206360
     [Google Scholar]
  105. KivityS. ZafrirY. LoebsteinR. PauznerR. MouallemM. MayanH. Clinical characteristics and risk factors for low dose methotrexate toxicity: A cohort of 28 patients.Autoimmun. Rev.201413111109111310.1016/j.autrev.2014.08.02725172240
     [Google Scholar]
  106. BfArMMethotrexat: Dosierungsfehler.2019Available from: https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RV_STP/m-r/methotrexat-neu.html
  107. MHRAMethotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing.2020Available from: https://www.gov.uk/drug-safety-update/methotrexate-once-weekly-for-autoimmune-diseases-new-measures-to-reduce-risk-of-fatal-overdose-due-to-inadvertent-daily-instead-of-weekly-dosing
  108. InnesJ. JamiesonT. DalesR. LloydR. National quality improvement intervention to reduce high risk oral methotrexate prescribing.BMJ Open Qual.2022113e00194210.1136/bmjoq‑2022‑00194235961683
     [Google Scholar]
  109. EMANew measures to avoid potentially fatal dosing errors with methotrexate for inflammatory diseases.2019Available from: https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-new-measures-avoid-potentially-fatal-dosing-errors-methotrexate-inflammatory-diseases_en.pdf-0
  110. DetersM. StürzebecherA. Misadministration of methotrexate.Dtsch. Arztebl. Int.202211933-3456656736422875
     [Google Scholar]
  111. MacKennaB. CurtisH.J. WalkerA.J. CrokerR. BaconS. GoldacreB. Trends and variation in unsafe prescribing of methotrexate: A cohort study in English NHS primary care.Br. J. Gen. Pract.202070696e481e48810.3399/bjgp20X71099332571771
     [Google Scholar]
  112. CairnsR. BrownJ.A. LynchA.M. RobinsonJ. WylieC. BuckleyN.A. A decade of Australian methotrexate dosing errors.Med. J. Aust.20162041038410.5694/mja15.0124227256650
     [Google Scholar]
  113. NimkarS.V. YelneP. GaidhaneS.A. AcharyaS. KumarS. Fatal manifestations of methotrexate overdose in case of psoriasis due to dosing error.Cureus20221410e3004110.7759/cureus.3004136381811
     [Google Scholar]
  114. BalkowF. Methotrexate, investigation into the causes of a fatal overdose. Institute of Legal Medicine, Ludwig Maximilian University, Munich..LMU Munich2010
     [Google Scholar]
  115. SchmiegelowK. Advances in individual prediction of methotrexate toxicity: A review.Br. J. Haematol.2009146548950310.1111/j.1365‑2141.2009.07765.x19538530
     [Google Scholar]
  116. DGRhDeutsche Gesellschaft für Rheumatologie: Therapie mit Methotrexat: Eine praxisorientierte Information für den behandelnden Arzt.2014Available from: https://dgrh.de/dam/jcr:0fff25d9-b2ea-4fca-94bc-06b03a0e09fd/methotrexat_arzt_2014_07.pdf
  117. LedinghamJ. GullickN. IrvingK. GorodkinR. ArisM. BurkeJ. GordonP. ChristidisD. GallowayS. HayesE. JeffriesA. MercerS. MooneyJ. van LeuvenS. GallowayJ. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease- modifying anti-rheumatic drugs.Rheumatology201756686586810.1093/rheumatology/kew47928339817
     [Google Scholar]
  118. MorelandL.W. Rheumatology and immunology therapy: A to Z essentials.Springer Berlin Heidelberg2004VIII92310.1007/3‑540‑29662‑X
     [Google Scholar]
  119. RamseyL.B. BalisF.M. O’BrienM.M. SchmiegelowK. PauleyJ.L. BleyerA. WidemannB.C. AskenaziD. BergeronS. ShiraliA. SchwartzS. VinksA.A. HeldrupJ. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance.Oncologist2018231526110.1634/theoncologist.2017‑024329079637
     [Google Scholar]
  120. GBAGemeinsamer Bundesausschuss: Bewertung von Arzneimitteln für seltene Leiden nach § 35a Absatz 1 Satz 11 i. V. m. Kapitel 5 § 12 Nr. 1 Satz 2 VerfO, Wirkstoff: Glucarpidase.2022Available from: https://www.g-ba.de/downloads/92-975-5662/ 2022-04-15_Nutzenbewertung-G-BA_Glucarpidase_D-806.pdf
  121. NHSGlucarpidase for the urgent treatment of methotrexate-induced renal dysfunction.2022Available from: https://www.england.nhs.uk/wp-content/uploads/2022/12/ccp-glucarpidase-for-the-urgent-treatment-of-methotrexate-v2.pdf
/content/journals/crr/10.2174/0115733971317122240626053727
Loading
Methotrexate - Safe Backbone for the Treatment of Rheumatoid Arthritis
Curr. Rheumatol. Rev. 21, 169 (2025); https://doi.org/10.2174/0115733971317122240626053727
/content/journals/crr/10.2174/0115733971317122240626053727
/content/journals/crr/10.2174/0115733971317122240626053727
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): folic acid; intoxication; Methotrexate; MTX; rheumatoid arthritis; safety

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test